A double-blind, placebo-controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder.

@article{Arnold2004ADP,
  title={A double-blind, placebo-controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder.},
  author={Lawrence Eugene Arnold and Ronald L Lindsay and Charlene Conners and Sharon B. Wigal and Alan J Levine and Diane E Johnson and Scott A. West and Rahul B. Sangal and Timothy P. Bohan and Jerome B. Zeldis},
  journal={Journal of child and adolescent psychopharmacology},
  year={2004},
  volume={14 4},
  pages={542-54}
}
OBJECTIVES d,l-threo-methylphenidate HCl (D,L-MPH) is the most common treatment of attention deficit hyperactivity disorder (ADHD). A previous report showed placebo-controlled efficacy for the purified d-isomer (dexmethylphenidate hydrochloride, d-MPH, Focalin) with a 2:1 potency compared to dl, and suggested a 6-hour duration of action. This study complements that report by studying the effect of placebo-controlled discontinuation and retesting the duration of action. METHODS A 6-week, open… CONTINUE READING